06.02.2024 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023. The Company is hosting a conference call today, February 6, 2024, at 4:30 p.m. ET to discuss the results. .
Updates in women s heart health: low statin use; women in CV fellowships; and more healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p
BridgeBio Pharma (BBIO) Reports Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint and frequency of cardiovascular-related hospitalization ), with a Win Ratio of 1.8 - Acoramidis.